Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis

Shouichi Ohga, Kenji Okada, Kohji Ueda, Hidetoshi Takada, Mitsuhiro Ohta, Tomonobu Aoki, Naoko Kinukawa, Sumio Miyazaki, Toshiro Hara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: cerebrospinal fluid (CSF) levels of interleukin (IL)-1 β and tumor necrosis factor (TNF) α were measured to assess the effect and application of dexamethasone (Dex) therapy for bacterial meningitis. Methods: associations between clinical findings and CSF parameters were first investigated, and prognosis was compared between 25 patients with Dex and 12 without Dex therapy. Results: patients with the presence of disturbed consciousness showed higher CSF levels of TNF α (mean: 3015 pg/ml) or protein (mean: 215 mg/dl) than those without it (both, P < 0.05). Simultaneous increase of TNF α (> 1000 pg/ml) and protein (> 100 mg/dl) was observed in 80% of patients with profoundly disturbed consciousness. Patients with Dex therapy presented higher TNF α/protein levels at diagnosis than those without Dex therapy (P < 0.05). Despite worse conditions at diagnosis, only one of 14 Dex-treated patients whose initial CSF TNF α levels exceeded 1000 pg/ml developed deafness. On the other hand, two of four patients without Dex therapy who had the same TNF α levels suffered from psychomotor retardation. The differences in the frequency of sequelae between those with and without Dex therapy were significant in patients showing high TNF α level (P < 0.05), but not in those showing high CSF levels of IL-1 β or protein. The logistic regression analysis indicated that high CSF protein level (P < 0.0001), or no Dex therapy (P = 0.0001) was the independent risk factor for sequelae. Conclusions: although the study number was small, our observations suggested that the neurologic severity, and implied that early Dex therapy might be beneficial for patients with prominently high TNF α levels.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalJournal of Infection
Volume39
Issue number1
DOIs
Publication statusPublished - Jul 1999

Fingerprint

Bacterial Meningitides
Dexamethasone
Cerebrospinal Fluid
Cytokines
Tumor Necrosis Factor-alpha
Therapeutics
Consciousness
Interleukin-1
Proteins
Cerebrospinal Fluid Proteins
Deafness
Secondary Prevention
Nervous System
Logistic Models
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis. / Ohga, Shouichi; Okada, Kenji; Ueda, Kohji; Takada, Hidetoshi; Ohta, Mitsuhiro; Aoki, Tomonobu; Kinukawa, Naoko; Miyazaki, Sumio; Hara, Toshiro.

In: Journal of Infection, Vol. 39, No. 1, 07.1999, p. 55-60.

Research output: Contribution to journalArticle

Ohga, S, Okada, K, Ueda, K, Takada, H, Ohta, M, Aoki, T, Kinukawa, N, Miyazaki, S & Hara, T 1999, 'Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis', Journal of Infection, vol. 39, no. 1, pp. 55-60. https://doi.org/10.1016/S0163-4453(99)90103-2
Ohga, Shouichi ; Okada, Kenji ; Ueda, Kohji ; Takada, Hidetoshi ; Ohta, Mitsuhiro ; Aoki, Tomonobu ; Kinukawa, Naoko ; Miyazaki, Sumio ; Hara, Toshiro. / Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis. In: Journal of Infection. 1999 ; Vol. 39, No. 1. pp. 55-60.
@article{e41d6a662f784d2eb4404552d361d6df,
title = "Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis",
abstract = "Objectives: cerebrospinal fluid (CSF) levels of interleukin (IL)-1 β and tumor necrosis factor (TNF) α were measured to assess the effect and application of dexamethasone (Dex) therapy for bacterial meningitis. Methods: associations between clinical findings and CSF parameters were first investigated, and prognosis was compared between 25 patients with Dex and 12 without Dex therapy. Results: patients with the presence of disturbed consciousness showed higher CSF levels of TNF α (mean: 3015 pg/ml) or protein (mean: 215 mg/dl) than those without it (both, P < 0.05). Simultaneous increase of TNF α (> 1000 pg/ml) and protein (> 100 mg/dl) was observed in 80{\%} of patients with profoundly disturbed consciousness. Patients with Dex therapy presented higher TNF α/protein levels at diagnosis than those without Dex therapy (P < 0.05). Despite worse conditions at diagnosis, only one of 14 Dex-treated patients whose initial CSF TNF α levels exceeded 1000 pg/ml developed deafness. On the other hand, two of four patients without Dex therapy who had the same TNF α levels suffered from psychomotor retardation. The differences in the frequency of sequelae between those with and without Dex therapy were significant in patients showing high TNF α level (P < 0.05), but not in those showing high CSF levels of IL-1 β or protein. The logistic regression analysis indicated that high CSF protein level (P < 0.0001), or no Dex therapy (P = 0.0001) was the independent risk factor for sequelae. Conclusions: although the study number was small, our observations suggested that the neurologic severity, and implied that early Dex therapy might be beneficial for patients with prominently high TNF α levels.",
author = "Shouichi Ohga and Kenji Okada and Kohji Ueda and Hidetoshi Takada and Mitsuhiro Ohta and Tomonobu Aoki and Naoko Kinukawa and Sumio Miyazaki and Toshiro Hara",
year = "1999",
month = "7",
doi = "10.1016/S0163-4453(99)90103-2",
language = "English",
volume = "39",
pages = "55--60",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis

AU - Ohga, Shouichi

AU - Okada, Kenji

AU - Ueda, Kohji

AU - Takada, Hidetoshi

AU - Ohta, Mitsuhiro

AU - Aoki, Tomonobu

AU - Kinukawa, Naoko

AU - Miyazaki, Sumio

AU - Hara, Toshiro

PY - 1999/7

Y1 - 1999/7

N2 - Objectives: cerebrospinal fluid (CSF) levels of interleukin (IL)-1 β and tumor necrosis factor (TNF) α were measured to assess the effect and application of dexamethasone (Dex) therapy for bacterial meningitis. Methods: associations between clinical findings and CSF parameters were first investigated, and prognosis was compared between 25 patients with Dex and 12 without Dex therapy. Results: patients with the presence of disturbed consciousness showed higher CSF levels of TNF α (mean: 3015 pg/ml) or protein (mean: 215 mg/dl) than those without it (both, P < 0.05). Simultaneous increase of TNF α (> 1000 pg/ml) and protein (> 100 mg/dl) was observed in 80% of patients with profoundly disturbed consciousness. Patients with Dex therapy presented higher TNF α/protein levels at diagnosis than those without Dex therapy (P < 0.05). Despite worse conditions at diagnosis, only one of 14 Dex-treated patients whose initial CSF TNF α levels exceeded 1000 pg/ml developed deafness. On the other hand, two of four patients without Dex therapy who had the same TNF α levels suffered from psychomotor retardation. The differences in the frequency of sequelae between those with and without Dex therapy were significant in patients showing high TNF α level (P < 0.05), but not in those showing high CSF levels of IL-1 β or protein. The logistic regression analysis indicated that high CSF protein level (P < 0.0001), or no Dex therapy (P = 0.0001) was the independent risk factor for sequelae. Conclusions: although the study number was small, our observations suggested that the neurologic severity, and implied that early Dex therapy might be beneficial for patients with prominently high TNF α levels.

AB - Objectives: cerebrospinal fluid (CSF) levels of interleukin (IL)-1 β and tumor necrosis factor (TNF) α were measured to assess the effect and application of dexamethasone (Dex) therapy for bacterial meningitis. Methods: associations between clinical findings and CSF parameters were first investigated, and prognosis was compared between 25 patients with Dex and 12 without Dex therapy. Results: patients with the presence of disturbed consciousness showed higher CSF levels of TNF α (mean: 3015 pg/ml) or protein (mean: 215 mg/dl) than those without it (both, P < 0.05). Simultaneous increase of TNF α (> 1000 pg/ml) and protein (> 100 mg/dl) was observed in 80% of patients with profoundly disturbed consciousness. Patients with Dex therapy presented higher TNF α/protein levels at diagnosis than those without Dex therapy (P < 0.05). Despite worse conditions at diagnosis, only one of 14 Dex-treated patients whose initial CSF TNF α levels exceeded 1000 pg/ml developed deafness. On the other hand, two of four patients without Dex therapy who had the same TNF α levels suffered from psychomotor retardation. The differences in the frequency of sequelae between those with and without Dex therapy were significant in patients showing high TNF α level (P < 0.05), but not in those showing high CSF levels of IL-1 β or protein. The logistic regression analysis indicated that high CSF protein level (P < 0.0001), or no Dex therapy (P = 0.0001) was the independent risk factor for sequelae. Conclusions: although the study number was small, our observations suggested that the neurologic severity, and implied that early Dex therapy might be beneficial for patients with prominently high TNF α levels.

UR - http://www.scopus.com/inward/record.url?scp=0032821096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032821096&partnerID=8YFLogxK

U2 - 10.1016/S0163-4453(99)90103-2

DO - 10.1016/S0163-4453(99)90103-2

M3 - Article

C2 - 10468130

AN - SCOPUS:0032821096

VL - 39

SP - 55

EP - 60

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

IS - 1

ER -